PTEN and prostate cancer: In agreement with this prediction, the rotenone derivative deguelin suppressed tumour growth in a prostate cancer mouse model lacking both PTEN and Trp53. 72 Overall, these data provide evidence that targeting oxidative phosphorylation might be an effective therapeutic approach for prostate cancer.